[{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0.64000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.64000000000000001,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Bayer"}]

Find Clinical Drug Pipeline Developments & Deals by Hua Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Hua Medicine shall be responsible for clinical development, registration, product supply and distribution of dorzagliatin, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in Ch...

                          Brand Name : HMS5552

                          Molecule Type : Small molecule

                          Upfront Cash : $43.3 milllion

                          August 17, 2020

                          Lead Product(s) : Dorzagliatin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Bayer AG

                          Deal Size : $635.8 million

                          Deal Type : Partnership

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.

                          Brand Name : HMS5552

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 01, 2020

                          Lead Product(s) : Dorzagliatin,Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 26, 2020

                          Lead Product(s) : Dorzagliatin,Empagliflozin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank